

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Essetifin SPA</u> <hr/> (Last) (First) (Middle) VIA SUDAFRICA, 20 <hr/> (Street) ROME L6 00144 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 09/11/2017	3. Issuer Name and Ticker or Trading Symbol <u>FENNEC PHARMACEUTICALS INC. [FENC]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 09/21/2017
		6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,931,579	D ⁽¹⁾	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

1. Name and Address of Reporting Person* <u>Essetifin SPA</u> <hr/> (Last) (First) (Middle) VIA SUDAFRICA, 20 <hr/> (Street) ROME L6 00144 <hr/> (City) (State) (Zip)		
---	--	--

1. Name and Address of Reporting Person* <u>Cavazza Enrico</u> <hr/> (Last) (First) (Middle) VIA SUDAFRICA, 20 <hr/> (Street) ROME L6 00144 <hr/> (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person*		
Cavazza Silvia		
(Last)	(First)	(Middle)
VIA SUDAFRICA, 20		
(Street)		
ROME	L6	00144
(City) (State) (Zip)		
1. Name and Address of Reporting Person*		
Cavazza Francesca		
(Last)	(First)	(Middle)
VIA SUDAFRICA, 20		
(Street)		
ROME	L6	00144
(City) (State) (Zip)		
1. Name and Address of Reporting Person*		
Cavazza Preta Martina		
(Last)	(First)	(Middle)
VIA SUDAFRICA, 20		
(Street)		
ROME	L6	00144
(City) (State) (Zip)		
1. Name and Address of Reporting Person*		
CAVAZZA PAOLO		
(Last)	(First)	(Middle)
VIA TESSERETE, 10		
(Street)		
LUGANO	V8	00000
(City) (State) (Zip)		

Explanation of Responses:

1. Dispositive power over the shares of common stock owned by Essetifin S.p.A. is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta, and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta, and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin S.p.A. except to the extent of any pecuniary interest therein.

Remarks:

This Form is being amended solely for the purpose of including the joint filers as signatories, which were omitted in the original filing pending receipt of EDGAR codes and to add the power of attorney, attached hereto. Exhibit List: Exhibit 24.1 - Power of Attorney Exhibit 24.2 - Power of Attorney Exhibit 24.3 - Power of Attorney Exhibit 24.4 - Power of Attorney Exhibit 24.5 - Power of Attorney Exhibit 99.1 - Joint Filers' Signatures

[Essetifin S.p.A. By: /s/ Marino Zigrossi](#) 10/04/2017
[/s/ Marino Zigrossi for Enrico Cavazza by power of attorney](#) 10/04/2017
[/s/ Marino Zigrossi for Silvia Cavazza by power of attorney](#) 10/04/2017
[/s/ Marino Zigrossi for Francesca Cavazza by power of attorney](#) 10/04/2017
[/s/ Marino Zigrossi for Martina Cavazza Preta by power of attorney](#) 10/04/2017

/s/ Fabio Poma for Paolo
Cavazza by power of attorney 10/04/2017

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned does hereby constitute and appoint Marino Zigrossi, with full power of substitution, as the true and lawful attorney-in-fact and agent of the undersigned, and authorizes and designates him to sign on behalf of the undersigned, and to file filings and any amendments thereto, with the Securities and Exchange Commission, made by or on behalf of the undersigned in respect of the beneficial ownership of equity securities of **REGENERX BIOPHARMACEUTICALS, INC.**; **SOLIGENIX, INC.** and **FENNEC PHARMACEUTICALS, INC.** held by the undersigned, directly, indirectly or beneficially, pursuant to Sections 13(d), 13(g) and 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules and regulations thereunder. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming any of the undersigned's responsibilities to comply with Sections 13(d), 13(g) or 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until withdrawn by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 25th day of September 2017.

/s/ Enrico Cavazza

Enrico Cavazza

POWER OF ATTORNEY

The undersigned does hereby constitute and appoint Marino Zigrossi, with full power of substitution, as the true and lawful attorney-in-fact and agent of the undersigned, and authorizes and designates him to sign on behalf of the undersigned, and to file filings and any amendments thereto, with the Securities and Exchange Commission, made by or on behalf of the undersigned in respect of the beneficial ownership of equity securities of **REGENERX BIOPHARMACEUTICALS, INC.**; **SOLIGENIX, INC.** and **FENNEC PHARMACEUTICALS, INC.** held by the undersigned, directly, indirectly or beneficially, pursuant to Sections 13(d), 13(g) and 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules and regulations thereunder. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming any of the undersigned's responsibilities to comply with Sections 13(d), 13(g) or 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until withdrawn by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 25th day of September 2017.

/s/ Silvia Cavazza

Silvia Cavazza

POWER OF ATTORNEY

The undersigned does hereby constitute and appoint Marino Zigrossi, with full power of substitution, as the true and lawful attorney-in-fact and agent of the undersigned, and authorizes and designates him to sign on behalf of the undersigned, and to file filings and any amendments thereto, with the Securities and Exchange Commission, made by or on behalf of the undersigned in respect of the beneficial ownership of equity securities of **REGENERX BIOPHARMACEUTICALS, INC.**; **SOLIGENIX, INC.** and **FENNEC PHARMACEUTICALS, INC.** held by the undersigned, directly, indirectly or beneficially, pursuant to Sections 13(d), 13(g) and 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules and regulations thereunder. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming any of the undersigned's responsibilities to comply with Sections 13(d), 13(g) or 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until withdrawn by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 25th day of September 2017.

/s/ Francesca Cavazza

Francesca Cavazza

POWER OF ATTORNEY

The undersigned does hereby constitute and appoint Marino Zigrossi, with full power of substitution, as the true and lawful attorney-in-fact and agent of the undersigned, and authorizes and designates him to sign on behalf of the undersigned, and to file filings and any amendments thereto, with the Securities and Exchange Commission, made by or on behalf of the undersigned in respect of the beneficial ownership of equity securities of **REGENERX BIOPHARMACEUTICALS, INC.**; **SOLIGENIX, INC.** and **FENNEC PHARMACEUTICALS, INC.** held by the undersigned, directly, indirectly or beneficially, pursuant to Sections 13(d), 13(g) and 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules and regulations thereunder. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming any of the undersigned's responsibilities to comply with Sections 13(d), 13(g) or 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until withdrawn by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 25th day of September 2017.

/s/ Martina Cavazza Preta

Martina Cavazza Preta

POWER OF ATTORNEY

The undersigned does hereby constitute and appoint each of Fabio Poma and Nicola Wullschleger, with full power of substitution, as the true and lawful attorney-in-fact and agent of the undersigned, and authorizes and designates each of the foregoing attorneys-in-fact to sign on behalf of the undersigned, and to file filings and any amendments thereto, with the Securities and Exchange Commission, made by or on behalf of the undersigned in respect of the beneficial ownership of equity securities of **FENNEC PHARMACEUTICALS, INC.** held by the undersigned, directly, indirectly or beneficially, pursuant to Sections 13(d), 13(g) and 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules and regulations thereunder. Each of the undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of each of the undersigned, are not assuming any of the undersigned's responsibilities to comply with Sections 13(d), 13(g) or 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until withdrawn by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, each of the undersigned has caused this Power of Attorney to be executed as of this 20th day of September 2017.

/s/ Paolo Cavazza

Paolo Cavazza

JOINT FILERS' SIGNATURES

ESSETIFIN S.P.A.

By: /s/ Marino Zigrossi
Name: Marino Zigrossi
Title: Director
Date: October 2, 2017

Enrico Cavazza

By: /s/ Marino Zigrossi
Name: Marino Zigrossi
Title: Attorney-in-Fact
Date: October 2, 2017

Silvia Cavazza

By: /s/ Marino Zigrossi
Name: Marino Zigrossi
Title: Attorney-in-Fact
Date: October 2, 2017

Francesca Cavazza

By: /s/ Marino Zigrossi
Name: Marino Zigrossi
Title: Attorney-in-Fact
Date: October 2, 2017

Martina Cavazza Preta

By: /s/ Marino Zigrossi
Name: Marino Zigrossi
Title: Attorney-in-Fact
Date: October 2, 2017

Paolo Cavazza

By: /s/ Fabio Poma
Name: Fabio Poma
Title: Attorney-in-Fact
Date: October 2, 2017